Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Alessandro Gronchi, Aisha Miah, Angelo Paolo Dei Tos, +74

Annals of Oncology

Surgical OncologySoft Tissue SurgeryVisceral SarcomasSurgical PathologyHistopathology +4

Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Paolo G. Casali, Jean‐Yves Blay, N. Abecassis, +68

Annals of Oncology

Surgical OncologyGastrointestinal OncologyMedicineSurgical PathologyGastroenterology +9

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Sandra J. Strauss, Anna Maria Frezza, N. Abecassis, +76

Annals of Oncology

Bone DiseaseBone SarcomasSurgical OncologyBone ImagingMedicine +3

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

James Spicer, Aurélien Marabelle, Jean‐François Baurain, +18

Clinical Cancer Research

Prediction of¹⁷⁷Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study

Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, +19

Journal of Nuclear Medicine

A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.

Patrick Schöffski, Philippe Aftimos, Christophe Massard, +5

Journal of Clinical Oncology

Tumor BiologyOncologyMedicinePharmacologyMedullary Thyroid Cancer +13

A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.

Milind Javle, John Bridgewater, Olumide B. Gbolahan, +9

Journal of Clinical Oncology

Phase I/ii StudyArginase Inhibitor Incb001158Cancer ManagementImmunologyImmunotherapeutics +20

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial

Philippe Aftimos, Laura Polastro, Lieveke Ameye, +10

European Journal of Cancer

Metastatic Breast CancerBreast OncologyAccess ProgramMedicineCancer Management +7

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report

Hasnae Alaoui Mhamdi, Hampig Raphaël Kourié, Christiane Jungels, +3

Journal of Medical Case Reports

Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.

Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki, +11

Journal of Clinical Oncology

Ro SaturationCancer ManagementImmunologyImmunoeditingBi 765063 +19